U.S. Markets closed

Pfizer acquires NextWave Pharmaceuticals

Pfizer has completed its acquisition of NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. Pfizer now holds exclusive North American commercialization rights to Quillivant XR (methylphenidate hydrochloride) for extended-release oral suspension, CII, the first once-daily liquid medication approved by the FDA on September 27 for the treatment of ADHD. Quillivant XR is expected to be available in pharmacies in the U.S. in January 2013.